BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 07, 2003
 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Cellectis S.A.

Paris, France

Technology: Therapeutic genome engineering

Disease focus: Viral diseases and metabolic disease

Clinical status: Preclinical


Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >